Michel F B, Dussourd D'Hinterland L, Bousquet J, Pinel A M, Normier G
Infect Immun. 1978 Jun;20(3):760-9. doi: 10.1128/iai.20.3.760-769.1978.
We have studied a new vaccine of ribosomal nature associated with glycoprotein cell walls from Klebsiella pneumoniae which served as an immunoadjuvant. Thus vaccine was administered by the aerosol route to working men free of any important disease, especially of respiratory disease. A total of 104 men working for the Commissariat à l'Energie Atomique, all volunteers, were randomly placed into two groups. During the first period, 51 patients (group I) were vaccinated three times a week during 5 weeks, and the second group was used as control. During the second period, which started on day 225, the control group received the vaccine, and the first group was revaccinated. Results of this experience show a significant difference in the immunity of the two groups. The specific antibodies increased with vaccination as illustrated by chi-square test (Yates correction), which corresponds to an independent probability equal to 0 (P = 0.5 X 10-4).
我们研究了一种与肺炎克雷伯菌糖蛋白细胞壁相关的核糖体性质的新型疫苗，该疫苗用作免疫佐剂。通过气雾剂途径将这种疫苗接种给没有任何重大疾病，尤其是没有呼吸道疾病的在职男性。总共有104名受雇于法国原子能委员会的男性，均为志愿者，被随机分为两组。在第一阶段，51名患者（第一组）在5周内每周接种三次疫苗，第二组用作对照。在第225天开始的第二阶段，对照组接受疫苗接种，第一组进行再次接种。该实验结果表明两组的免疫力存在显著差异。如卡方检验（耶茨校正）所示，特异性抗体随疫苗接种而增加，其对应于独立概率等于0（P = 0.5×10-4）。
